Neobiosis, LLC
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Safety, Efficacy, and Dosing of VIX001 in Patients With Neurological Symptoms of Post Acute COVID-19 Syndrome (PACS). (NCT05947617) | Neobiosis, LLC | 2023-10-01 |
Track Neobiosis, LLC automatically
Every clearance here is in the API, with alerts when new ones post.